Skip to main content
CADL
NASDAQ Life Sciences

Candel's Aglatimagene Shows 24.5-Month Survival in NSCLC Patients Failing Immunotherapy

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.4
Mkt Cap
$798.854M
52W Low
$4.35
52W High
$14
52W Position info
139% above low
Off High info
26% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CADL has more than doubled off its 52-week low of $4.35.

Summary

Candel published final Phase 2a data in the Journal for ImmunoTherapy of Cancer showing aglatimagene plus valacyclovir achieved a median overall survival of 24.5 months in evaluable patients with unresectable stage III/IV NSCLC who had inadequate response to immune checkpoint inhibitors. That compares to 9.8-11.8 months for standard-of-care docetaxel. In the subgroup with progressive disease on ICI (n=41), mOS was 21.5 months, and 37% remained alive beyond 24 months. Non-squamous patients did even better: mOS of 25.4 months, with 14 of 15 surviving beyond 24 months. Mechanistic data showed 69% of patients with multiple lesions had systemic clinical response, indicating an abscopal effect. Safety was manageable with mostly grade 1-2 flu-like symptoms and 13.7% grade 3 treatment-related adverse events. This follows the ASTRO 2026 biomarker presentation on September 30 and supports the ongoing pivotal Phase 3 AURORA trial in metastatic non-squamous NSCLC. The peer-reviewed publication provides independent validation and could strengthen the case for regulatory discussions. Watch for AURORA trial enrollment updates and any FDA interactions.

At the time of this announcement, CADL was trading at $10.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $798.9M. The 52-week trading range was $4.35 to $14.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $6.15 info
Change: +$1.04 (+20%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.15 info
Change: -$2.24 (-27%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.15 info
Change: -$2.24 (-27%) info
Market Cap: $486.365M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $6.15 info
Change: -$4.81 (-44%) info
Market Cap: $486.365M info
CADL
Sep 09, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.14
Real-time Price: $6.15 info
Change: -$5.99 (-49%) info
Market Cap: $486.365M info